URSO, LOREDANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.248
EU - Europa 344
AS - Asia 318
Totale 2.910
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.240
SG - Singapore 153
CN - Cina 137
IT - Italia 135
SE - Svezia 56
DE - Germania 43
FI - Finlandia 41
FR - Francia 37
GB - Regno Unito 15
IN - India 14
CA - Canada 8
NL - Olanda 5
VN - Vietnam 5
RU - Federazione Russa 4
TW - Taiwan 4
UA - Ucraina 4
HK - Hong Kong 2
IE - Irlanda 2
CZ - Repubblica Ceca 1
IR - Iran 1
JP - Giappone 1
LT - Lituania 1
PH - Filippine 1
Totale 2.910
Salva come PNG Salva come JPEG
Città #
Fairfield 451
Chandler 206
Woodbridge 173
Ashburn 166
Houston 139
Singapore 134
Cambridge 133
Seattle 124
Wilmington 111
San Diego 98
Santa Clara 60
Ann Arbor 59
Boardman 51
Padova 44
Medford 39
Princeton 39
Helsinki 37
Guangzhou 34
Des Moines 25
Munich 24
Roxbury 21
Beijing 19
New York 13
Shanghai 13
Milan 12
Nanjing 8
Ottawa 8
Nanchang 6
Ogden 6
Paris 6
Dong Ket 5
London 5
Rome 5
Hsinchu County 4
Kharkiv 4
Selvazzano Dentro 4
Changsha 3
Los Angeles 3
Norwalk 3
Washington 3
Acton 2
Amsterdam 2
Bitonto 2
Castagnole 2
Chongqing 2
Columbus 2
Dallas 2
Dublin 2
Fisciano 2
Geislingen an der Steige 2
Genoa 2
Hebei 2
Kunming 2
Naples 2
Nepi 2
Pune 2
Redmond 2
Redwood City 2
Shenyang 2
Treviso 2
Verona 2
Zhengzhou 2
Borås 1
Bresso 1
Cagliari 1
Caloocan City 1
Camparada 1
Chiswick 1
Cinisello Balsamo 1
Falkenstein 1
Ferrara 1
Forlì 1
Hefei 1
Hong Kong 1
Hounslow 1
Jiaxing 1
Kilburn 1
Lecce 1
Legnaro 1
Mumbai 1
Orange 1
Phoenix 1
Portland 1
Prague 1
Puyang Chengguanzhen 1
Quzhou 1
San Mateo 1
Surat 1
Tianjin 1
Vicenza 1
Xian 1
Totale 2.371
Salva come PNG Salva come JPEG
Nome #
211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis 186
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 185
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intra-tumor heterogeneity over time 133
Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma 124
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists 116
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 104
Metabolic rewiring and redox alterations in malignant pleural mesothelioma 102
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: Correlation with pathological and clinical data 92
Effects of sulfonylureas on tumor growth: A review of the literature 89
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 89
Synergistic antitumor activity of recombinant human Apo2L/Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma 86
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment 85
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 84
Liquid biopsy in malignant pleural mesothelioma: State of the art, pitfalls, and perspectives 82
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer 81
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 75
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 71
Cisplatin reduces endothelial cell migration via regulation of type 2-matrix metalloproteinase activity 68
Functions of epidermal growth factor receptor in cisplatin response of thyroid cells 68
Differential response of normal, dedifferentiated and transformed thyroid cell lines to cisplatin treatment 68
Angiotensin II induces MMP 2 activity via FAK/JNK pathway in human endothelial cells 66
Effects of cisplatin on matrix metalloproteinase-2 in transformed thyroid cells 65
The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers 65
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification 58
Epigenetic Regulation of miR-212 Expression in Lung Cancer 56
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype 55
miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED 54
Differential functions of PKC-delta and PKC-zeta in cisplatin response of normal and transformed thyroid cells 53
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 51
mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells 50
Anti-apoptotic effects of protein kinase C-δ and c-fos in cisplatin-treated thyroid cells 45
[Pt(O,O′-acac)(γ-acac)(DMS)], a new Pt compound exerting fast cytotoxicity in MCF-7 breast cancer cells via the mitochondrial apoptotic pathway 44
New platinum(II) complexes containing both an O,O′-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells 44
Sublethal concentrations of the platinum(II) complex [Pt(O,O′-acac) (γ-acac)(DMS)] alter the motility and induce anoikis in MCF-7 cells 43
P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment 40
Targeted therapies in mesothelioma 37
PKC-ε-dependent cytosol-to-membrane translocation of pendrin in rat thyroid PC C13 cells 36
Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women 29
Mesothelin-targeted agents in mesothelioma 27
[Pt(O,O′-acac)(γ-acac)(DMS)], a new Pt compound exerting fast cytotoxicity in MCF-7 breast cancer cells via the mitochondrial apoptotic pathway (British Journal of Pharmacology (2007) 153, (34-49) DOI: 10.1038/sj.bjp.0707646) 23
Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus 20
Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets 17
Totale 2.966
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.190
article - articoli 12.857
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 333
Totale 26.380
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020181 0 0 0 0 0 0 21 38 48 29 29 16
2020/2021549 17 10 20 15 15 41 163 20 75 53 47 73
2021/2022724 40 44 38 15 74 198 35 33 43 68 37 99
2022/2023455 68 57 22 49 60 40 4 26 79 10 31 9
2023/2024289 17 42 41 23 12 42 22 3 10 35 22 20
2024/2025412 16 111 46 61 131 40 7 0 0 0 0 0
Totale 2.966